Photo of Paul Edward Goss, MBBCh

Goss, Paul Edward, MBBCh

  • Director, Breast Center Research
  • Co-Director, Breast Cancer Disease Program, DF/HCC


Accepting New Patients





Centers & Specialties

Cancer Center

Clinical Interests
  • Aromatase inhibitors as hormonal therapy for breast cancer
  • Breast cancer
Medical Education
  • PhD, University of London
  • MBBCH, University of Witwatersrand
  • Residency, Charing Cross Hospital|Residency, St. Helier Hospital
  • Fellowship, Royal Marsden Hospital
  • Boston: Massachusetts General Hospital
Insurances Accepted
  • Aetna Health Inc.
  • Beech Street
  • Blue Cross Blue Shield - Blue Care 65
  • Blue Cross Blue Shield - Indemnity
  • Blue Cross Blue Shield - Managed Care
  • Blue Cross Blue Shield - Partners Plus
  • Cigna (PAL #'s)
  • Fallon Community HealthCare
  • Great-West Healthcare (formally One Health Plan)
  • Harvard Pilgrim Health Plan - ACD
  • Harvard Pilgrim Health Plan - PBO
  • Health Care Value Management (HCVM)
  • Humana/Choice Care PPO
  • MassHealth
  • Medicare
  • Medicare - ACD
  • Neighborhood Health Plan - ACD
  • Neighborhood Health Plan - PBO
  • OSW - Maine
  • OSW - New Hampshire
  • OSW - Rhode Island
  • Private Health Care Systems (PHCS)
  • Senior Whole Health
  • TriCare
  • Tufts Health Plan
  • Unicare
  • United Healthcare (non-HMO) - ACD
  • United Healthcare (non-HMO) - PBO

Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.

Patient Age Group

Edit Profile

Research & Publications


Dr. Goss has published over 200 original articles on his research of breast cancer. Below are highlighted publications of NCIC CTG MA.17.

Whelan TJ, Goss PE, Ingle JN, Pater JL, Tu D, Pritchard K, Liu S, Shepherd LE, Palmer M, Robert NJ, Martino S, Muss HB. Assessment of Quality of Life in MA.17: A Randomized, Placebo-Controlled Trial of Letrozole After 5 Years of Tamoxifen in Postmenopausal Women. J Clin Oncol. 2005;23(28):6931-6940.

Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Pater JL. Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17. JClin Oncol. 2007;25(15):2006-11.

Goss PE, Ingle JN, Pater JL, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Tu D. Late Extended Adjuvant Treatment With Letrozole Improves Outcome in Women With Early-Stage Breast Cancer Who Complete 5 Years of Tamoxifen. J Clin Oncol. 2008;26(12):1948-55.7.

Edit Profile

News & Events

  • Gene-expression-based biomarker predicts long-term risk of breast cancer recurrence

    A comparison of three methods of predicting recurrence risk in women treated for estrogen-receptor-positive breast cancer finds that only the breast cancer index – a biomarker based on the expression levels of seven tumor-specific genes – accurately identifies patients who continue to be at risk after five years of estrogen-blocking treatment.

  • Biomarker predicts risk of breast cancer recurrence after tamoxifen treatment

    A biomarker reflecting expression levels of two genes in tumor tissue may be able to predict which women treated for estrogen-receptor-positive breast cancer should receive a second estrogen-blocking medication after completing tamoxifen treatment.

  • Breakthroughs from ASCO

    Cancer Center investigators and physician-scientists share promising research and treatment developments in breast cancer, melanoma and more.


55 Fruit Street
Boston, MA 02114-2696
Phone 1: 617-726-6500
Phone 2: 617-724-3118
Fax: 617-724-1079

Edit Profile

Back to Top